{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T17:14:13Z","timestamp":1760116453300,"version":"build-2065373602"},"reference-count":22,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T00:00:00Z","timestamp":1730937600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>(1) Background and Objectives: Vitamin D is implicated in the pathogenesis of Chronic Kidney Disease\u2014Mineral and Bone Disorder (CKD-MBD) in hemodialysis (HD) patients, including the development of secondary hyperparathyroidism (SHP). While cholecalciferol supplementation is recommended for vitamin D deficiency correction, its impact on CKD-MBD remains inconsistent. The aim of this observational prospective study was to assess the effect of cholecalciferol in achieving high\u2013normal serum 25-hydroxycholecalciferol (25(OH)D &gt; 75 ng\/mL) levels and its impact on CKD-MBD biochemical markers, including 1,25-dihydroxycholecalciferol (1,25(OH)2D) and parathormone (PTH) in HD patients. The study also evaluated the maintenance dosage required to sustain 25(OH)D levels within the 50\u201375 ng\/mL range. (2) Materials and Methods: A total of 22 HD patients with baseline 25(OH)D levels 30\u201350 ng\/mL received cholecalciferol (70,000 IU\/week) to achieve the target serum 25(OH)D &gt; 75 ng\/mL. Baseline data on calcium, phosphate, 1\u201384 PTH, 25(OH)D, and 1,25(OH)2D serum levels were compared with the data when 25(OH)D &gt; 75 ng\/mL was targeted or when the highest 25(OH)D levels were noted. (3) Results: Cholecalciferol significantly improved vitamin D status in HD patients, with 73% reaching the target 25(OH)D level &gt;75 ng\/mL in a median time of 7.5 weeks, with a median total dose of 525,000 IU. This was associated with a significant rise in 1,25(OH)2D, decrease in 1\u201384 PTH, and no significant effect on calcium and phosphate levels. The median maintenance dose of cholecalciferol was established at 30,000 IU\/week. (4) Conclusions: The findings support the use of cholecalciferol targeting high normal 25(OH)D levels to improve biochemical markers of CKD-MBD in HD patients.<\/jats:p>","DOI":"10.3390\/medicina60111831","type":"journal-article","created":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T06:41:22Z","timestamp":1730961682000},"page":"1831","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hemodialysis Patients May Benefit from Cholecalciferol Treatment Targeting High Level of 25(OH)D"],"prefix":"10.3390","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6722-1540","authenticated-orcid":false,"given":"Agnieszka","family":"Tarasewicz","sequence":"first","affiliation":[{"name":"Department of Nephrology, Transplantology and Internal Medicine, Medical University of Gda\u0144sk, 80-210 Gda\u0144sk, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ma\u0142gorzata","family":"D\u0105browska","sequence":"additional","affiliation":[{"name":"Central Clinical Laboratory, University Clinical Center, 80-952 Gda\u0144sk, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5766-1913","authenticated-orcid":false,"given":"Micha\u0142","family":"Komorniczak","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Transplantology and Internal Medicine, Medical University of Gda\u0144sk, 80-210 Gda\u0144sk, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnieszka","family":"Zakrzewska","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Transplantology and Internal Medicine, Medical University of Gda\u0144sk, 80-210 Gda\u0144sk, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bogdan","family":"Biedunkiewicz","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Transplantology and Internal Medicine, Medical University of Gda\u0144sk, 80-210 Gda\u0144sk, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8773-9649","authenticated-orcid":false,"given":"Sylwia","family":"Ma\u0142gorzewicz","sequence":"additional","affiliation":[{"name":"Department of Clinical Nutrition, Medical University of Gda\u0144sk, 80-210 Gda\u0144sk, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2432-6350","authenticated-orcid":false,"given":"Magdalena","family":"Jankowska","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Transplantology and Internal Medicine, Medical University of Gda\u0144sk, 80-210 Gda\u0144sk, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarzyna","family":"Jasiulewicz","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Transplantology and Internal Medicine, Medical University of Gda\u0144sk, 80-210 Gda\u0144sk, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia","family":"P\u0142onka","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Transplantology and Internal Medicine, Medical University of Gda\u0144sk, 80-210 Gda\u0144sk, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8210-8063","authenticated-orcid":false,"given":"Alicja","family":"D\u0119bska-\u015alizie\u0144","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Transplantology and Internal Medicine, Medical University of Gda\u0144sk, 80-210 Gda\u0144sk, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5515-5072","authenticated-orcid":false,"given":"Leszek","family":"Tylicki","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Transplantology and Internal Medicine, Medical University of Gda\u0144sk, 80-210 Gda\u0144sk, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,11,7]]},"reference":[{"key":"ref_1","first-page":"65","article-title":"Management of Chronic Kidney Disease\u2014Mineral and Bone Disorder","volume":"16","author":"Hryciuk","year":"2023","journal-title":"Ren. Dis. Transplant. Forum"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Pludowski, P., Takacs, I., Boyanov, M., Belaya, Z., Diaconu, C.C., Mokhort, T., Zherdova, N., Rasa, I., Payer, J., and Pilz, S. (2022). Clinical Practice in the Prevention, Diagnosis and Treatment of Vitamin D Deficiency: A Central and Eastern European Expert Consensus Statement. Nutrients, 14.","DOI":"10.3390\/nu14071483"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"P\u0142udowski, P., Kos-Kud\u0142a, B., Walczak, M., Fal, A., Jackowska, T., Helwich, E., and Mazur, A. (2023). Guidelines for Preventing and Treating Vitamin D Deficiency: A 2023 Update in Poland. Nutrients, 5.","DOI":"10.3390\/nu15030695"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group (2017). KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int. Suppl., 7, 1\u201359.","DOI":"10.1016\/j.kisu.2017.04.001"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1053\/j.jrn.2013.07.003","article-title":"Prevalence of Vitamin D Deficiency and Effects of Supplementation with Cholecalciferol in Patients with Chronic Kidney Disease","volume":"24","author":"Kim","year":"2014","journal-title":"J. Ren. Nutr."},{"key":"ref_6","first-page":"197","article-title":"Treatment of secondary hyperparathyroidism hemodialysis patients in Poland\u2014Real life scenario","volume":"20","author":"Zawierucha","year":"2016","journal-title":"Nefrol. Dial. Pol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Tarasewicz, A., Komorniczak, M., Zakrzewska, A., Biedunkiewicz, B., Ma\u0142gorzewicz, S., Jankowska, M., Jasiulewicz, K., P\u0142onka, N., D\u0105browska, M., and D\u0119bska-\u015alizie\u0144, A. (2024). The Efficacy and Safety of High-Dose Cholecalciferol Therapy in Hemodialysis Patients. Biomedicines, 12.","DOI":"10.3390\/biomedicines12020377"},{"key":"ref_8","first-page":"87","article-title":"Cholecalciferol versus Calcitriol to Manage Secondary Hyperparathyroidism in Hemodialysis Patients","volume":"5","author":"Omrani","year":"2018","journal-title":"J. Parathyr. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.12659\/MSM.892315","article-title":"Long-Term Cholecalciferol Administration in Hemodialysis Patients: A Single-Center Randomized Pilot Study","volume":"20","author":"Mieczkowski","year":"2014","journal-title":"Med. Sci. Moni."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"781191","DOI":"10.3389\/fmed.2021.781191","article-title":"Cholecalciferol vs. Small Doses of Alfacalcidol vs. Placebo in Chronic Kidney Disease Patients on Hemodialysis: A Randomized Parallel Group","volume":"8","author":"Kulicki","year":"2022","journal-title":"Study. Front. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"4016","DOI":"10.1093\/ndt\/gfn367","article-title":"High-Dose Cholecalciferol to Correct. Vitamin D Deficiency in Haemodialysis Patients","volume":"23","author":"Tokmak","year":"2008","journal-title":"Nephrol. Dial. Transpl."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1053\/j.ajkd.2014.04.020","article-title":"Original Investigation Biochemical Parameters After Cholecalciferol Repletion in Hemodialysis: Results From the VitaDial Randomized Trial","volume":"64","author":"Massart","year":"2014","journal-title":"Am. J. Kidney Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3799","DOI":"10.1093\/ndt\/gfp370","article-title":"Monthly Cholecalciferol Administration in Haemodialysis Patients: A Simple and Efficient Strategy for Vitamin D Supplementation","volume":"24","author":"Jean","year":"2009","journal-title":"Nephrol. Dial. Transpl."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"522","DOI":"10.3945\/ajcn.111.025502","article-title":"Efficacy and Safety of a Short Course of Very-High-Dose Cholecalciferol in Hemodialysis","volume":"95","author":"Wasse","year":"2012","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_15","first-page":"2773","article-title":"The Effects and Safety of High Dose Vitamin D3 in Hemodialysis Patients","volume":"21","author":"Guella","year":"2023","journal-title":"Pharm. Pract."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"c58","DOI":"10.1159\/000151534","article-title":"Evidence for Persistent Vitamin D 1-Alpha-Hydroxylation in Hemodialysis Patients: Evolution of Serum 1,25-Dihydroxycholecalciferol after 6 Months of 25-Hydroxycholecalciferol Treatment","volume":"110","author":"Jean","year":"2008","journal-title":"Nephron Clin. Pract."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/sdi.13066","article-title":"Long-Term Cholecalciferol Supplementation in Hemodialysis Patients: Effects on Mineral Metabolism, Inflammation, and Cardiac Parameters","volume":"36","author":"Matias","year":"2023","journal-title":"Semin. Dial."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1530\/EC-21-0372","article-title":"Low serum 1,25(OH)2D3 in end-stage renal disease: Is reduced 1\u03b1-hydroxylase the only problem?","volume":"10","author":"Huish","year":"2021","journal-title":"Endocr. Connect."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2147\/IJNRD.S97637","article-title":"Vitamin D Prohormone in the Treatment of Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease","volume":"10","author":"Friedl","year":"2017","journal-title":"Int. J. Nephrol. Renov. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1159\/000499187","article-title":"Rationale for Raising Current Clinical Practice Guideline Target for Serum 25-Hydroxyvitamin D in Chronic Kidney Disease","volume":"49","author":"Strugnell","year":"2019","journal-title":"Am. J. Nephrol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Marcinowska-Suchowierska, E., Kupisz-Urba\u0144ska, M., \u0141ukaszkiewicz, J., P\u0142udowski, P., and Jones, G. (2018). Vitamin D Toxicity\u2014A Clinical Perspective. Front. Endocrinol., 20.","DOI":"10.3389\/fendo.2018.00550"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Brandenburg, V., and Ketteler, M. (2022). Vitamin D and Secondary Hyperparathyroidism in Chronic and the Future. Nutrients, 14.","DOI":"10.3390\/nu14153009"}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/60\/11\/1831\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:28:09Z","timestamp":1760113689000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/60\/11\/1831"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,7]]},"references-count":22,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["medicina60111831"],"URL":"https:\/\/doi.org\/10.3390\/medicina60111831","relation":{},"ISSN":["1648-9144"],"issn-type":[{"type":"electronic","value":"1648-9144"}],"subject":[],"published":{"date-parts":[[2024,11,7]]}}}